跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 560 条关于
“claudin-18.2”
全部
560
临床试验
194
药物
121
机构
5
资讯
240
去年
Vyloy Leads Claudin 18.2 Targeted Therapy Revolution with 60+ Drug Candidates in Pipeline
去年
Claudin 18.2-Targeted Therapies Show Promise in Gastric and Other Cancers
去年
Triumvira Immunologics Presents Promising Phase 1 Data for TAC101-CLDN18.2 in Solid Tumors
去年
FDA Approves Zolbetuximab for Claudin 18.2-Positive Gastric and Gastroesophageal Junction Cancers
4年前
I-Mab's TJ-CD4B Receives FDA Orphan Drug Designation for Gastric Cancer Treatment
2年前
Elevation Oncology's EO-3021 Shows Promise in Claudin 18.2-Expressing Solid Tumors
7个月前
Claudin 18.2 Targeted Therapy Market Set to Exceed $800 Million by 2030 as Pipeline Expands Beyond Gastric Cancer
去年
FDA Grants Fast Track Designation to Elevation Oncology's EO-3021 for Gastric and GEJ Cancers
去年
Elevation Oncology's EO-3021 Shows Promise in Gastric and GEJ Cancers
上个月
Lepu Biopharma and AstraZeneca Announce Positive Phase III Results for CMG901 in Advanced Gastric Cancer
第 1 页,共 24 页
上一页
下一页